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Clinical Evaluation of a Vaccinia-Vectored Hantaan
Virus Vaccine
David J. McClain, Peter L. Summers, Stephen A. Harrison, Alan L. Schmaljohn, and
Connie S. Schmaljohn
Virology Division, United States Army Medical Research Institute of Infectious Diseases,
Fort Detrick, Frederick, Maryland
We evaluated a vaccinia-vectored vaccine for
hemorrhagic fever with renal syndrome in clini-
cal trials. A Phase I dose-escalation study in 16
volunteers divided into four groups demon-
strated that subcutaneous inoculation of ap-
proximately 107 plaque-forming units of the re-
combinant virus was safe and immunogenic.
Vaccination of a fifth group of 12 volunteers
indicated that neutralizing antibody titers to
both vaccinia virus and Hantaan virus were en-
hanced after a second inoculation. Comparing
two routes of vaccination showed that scarifica-
tion effectively induced neutralizing antibodies
in vaccinia virus-naive volunteers but that sub-
cutaneous inoculation was superior to scarifica-
tion in vaccinia virus-immune individuals. A
Phase II, double-blinded, placebo-controlled
clinical trial was conducted among 142 volun-
teers. Two subcutaneous vaccinations were ad-
ministered at 4-week intervals. Neutralizing an-
tibodies to Hantaan virus or to vaccinia virus
were detected in 72% or 98% of vaccinia virus-
naive volunteers, respectively. In contrast, only
26% of the vaccinia virus-immune volunteers de-
veloped neutralizing antibody responses to Han-
taan virus. J. Med. Virol. 60:77–85, 2000.
Published 2000 Wiley-Liss, Inc.†
KEY WORDS: Hantaan virus; hantavirus; vac-
cinia-vectored vaccine
INTRODUCTION
Hemorrhagic fever with renal syndrome (HFRS) is
caused by viruses in the Hantavirus genus of the fam-
ily Bunyaviridae. Hantaviruses persistently infect a
variety of rodents and are transmitted in infectious
aerosols of their urine, feces, and saliva. Prototype
Hantaan virus (HTNV) is carried by the striped field
mouse, Apodemus agrarius, and is responsible for a
severe form of HFRS throughout Asia. Seoul virus
(SEOV), which is carried by Rattus norvegicus, also
causes HFRS in Asia and has been found in rats world-
wide. Two other hantaviruses are known to cause
HFRS in Europe: Dobrava-Belgrade virus, carried by
Apodemus flavicollis (yellow-necked mouse) and Pu-
umala virus, carried by Clethrionomys glareolus (bank
voles) [reviewed in Schmaljohn and Hjelle, 1997]. The
widespread distribution of hantaviruses and the large
number of HFRS cases reported each year clearly in-
dicate the need for effective vaccines.
We previously reported the development of a recom-
binant vaccinia virus (VACV) vaccine for HFRS
[Schmaljohn et al., 1992]. The vaccine was produced by
inserting the HTNV M segment, encoding the envelope
glycoproteins (G1 and G2), and the S segment, encod-
ing the nucleocapsid protein (N), into the thymidine
kinase gene of the Connaught vaccine strain of VACV.
The HTNV M and S segments were under control of the
VACV 7.5-K or 11-K promoters, respectively [Schmal-
john et al., 1992]. In preclinical studies, the HFRS vac-
cine was similar to licensed VACV vaccines in that it
produced small, rapidly healing cutaneous lesions
when administered by scarification to nonhuman pri-
mates [Schmaljohn et al., 1994].
The protective efficacy of the candidate vaccine was
assayed in a hamster infectivity model. Although han-
tavirus-infected hamsters (and other laboratory ani-
mals) do not develop disease, viral antigen and RNA
can be observed in their lungs approximately 3 weeks
after they are infected [Schmaljohn et al., 1992; Chu et
al., 1995]. Using this model, we determined that a
single intramuscular injection of our recombinant
VACV vaccine protected most hamsters from challenge
with HTNV [Schmaljohn et al., 1992]. If the hamsters
had been previously immunized with a nonrecombi-
nant VACV, protection from HTNV challenge was
slightly reduced; however, a second intramuscular in-
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jection of the vaccine overcame preexisting immunity
to VACV and resulted in almost complete protection
from HTNV challenge [Schmaljohn et al., 1992]. Based
on these results, and additional preclinical safety stud-
ies, a final container vaccine was produced by Good
Manufacturing Practices for use in clinical studies.
Here we report findings of Phase I and Phase II trials
of the recombinant vaccine.
MATERIALS AND METHODS
Viruses, Cells, and Medium
HTNV, strain 76-118, and Sin Nombre virus (SNV),
strain CC107, were propagated in Vero E6 cells (Vero
C1008: ATCC CRL-1586) in Eagle’s minimum essential
medium (EMEM) containing 10% fetal bovine serum
(FBS), antibiotics, and amphotericin B.
Vaccine Construction
Details of the construction and selection of the re-
combinant vaccinia-vectored HTNV vaccine were de-
scribed previously [Schmaljohn et al., 1992]. Briefly,
the M segment of HTNV was cloned into the plasmid
vector pSC-11 downstream of the VACV 7.5 K pro-
moter [Chakrabarti et al., 1985]. The pSC-11 plasmid
contained a LacZ gene under control of VACV 11-K
promoter. This gene expresses b-galactosidase and is
used for color selection of recombinant viruses. We re-
moved the LacZ gene by digesting with restriction en-
zymes and replaced it with cDNA corresponding to the
S segment of HTNV [Schmaljohn et al., 1992]. Recom-
binant viruses were generated by homologous recom-
bination between the plasmid and the Connaught vac-
cine strain of VACV. Initial evaluation of the attenu-
ating properties of the vaccine were performed by
inoculation of chorioallantoic membranes of embryo-
nated chicken eggs, and by scarification of nonhuman
primates with the vaccine [Schmaljohn et al., 1994].
Neutralization and Viremia Assays
Sera were diluted serially twofold beginning at a 1:10
dilution in EMEM supplemented with 2% heat-
inactivated FBS, antibiotics, and amphotericin B, and
mixed with an equal volume of medium containing 50–
100 plaque-forming units (PFU) of HTNV per 200 ml
and 2% normal human serum. The virus-serum mix-
ture was incubated for 1 hr at 37°C and then overnight
at 4°C. Selected Phase I samples were assayed by
plaque reduction neutralization tests (PRNT) and by a
neutralizing enzyme-linked immunosorbent assay
(NT-ELISA) simultaneously. Because the results cor-
related (R 4 0.82), Phase II samples were assayed only
by NT-ELISA.
For HTNV PRNT, confluent monolayers of Vero E6
cells grown in T-25 cm2 flasks were inoculated with 0.2
ml of the virus-antibody mixture. After adsorption for 1
hr at 35°C, each monolayer was overlaid with 7 ml of
0.6% agarose (SeaKem) containing HEPES-buffered,
Eagle’s basal medium with Earle’s salts, 5% heat inac-
tivated FBS, 1% dimethylsulfoxide (DMSO), and anti-
biotics. After incubation for 9 days at 35°C, each mono-
Fig. 1. Neutralizing antibody responses of volunteers in the phase
I, dose-escalation study, Groups 1–4, to (A) vaccinia virus (VACV) and
to (B) Hantaan virus (HTNV). Volunteers in Group 1 were VACV-
immune and volunteers in Groups 2, 3, and 4 were VACV-naive.
Plaque reduction neutralization tests (PRNT) were performed at vari-
ous times from 7 to 771 days after vaccination. To eliminate accessory
factor variation on neutralizing antibody activity, all sera were heated
at 56°C for 30 min prior to assay and a constant source of human
serum was added to each sample. The highest reciprocal titer mea-
sured at any of the assay points is displayed. Volunteers 1, 2, 3, 6, 9,
10, 11, 12, 14, 15, and 16 received a booster vaccination approximately
1 year after the initial vaccination. PRNT titers after the first (1°)
vaccination are indicated with closed symbols and those measured
after the booster vaccination with open symbols.
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layer was stained with 3 ml of the original overlay con-
taining 5% neutral red. The flasks were returned to the
incubator for one more day and the plaques were
counted. All specimens were tested in duplicate. Titers
are expressed as the reciprocal of the highest serum
dilution that resulted in a 50% reduction in plaque
counts (PRNT50%). In situ ELISA assays for VACV vi-
remia were performed on blood samples collected peri-
odically from the volunteers as described previously
[McClain et al., 1997]. Briefly, aliquots of serum were
added to confluent monolayers of Vero cells grown in
24- or 96-well plates. After 1 hr adsorption, fresh me-
dium was added to the wells and the plates were incu-
bated at 37°C for 4–6 days. Cells were then fixed with
formalin and incubated with hyperimmune mouse as-
citic fluid to VACV followed by enzymatically tagged
anti-mouse antibody and a chromogenic substrate
(ABTS).
The NT-ELISA for HTNV was performed on mono-
layers of Vero E6 cells grown in 96-well plates. Wells
were inoculated with 0.2 ml of the virus-antibody mix-
ture. Plates were incubated at 35°C in a humidified
atmosphere of 5% CO2 for 9 days. Cultures were de-
canted and fixed with 0.2 ml of 10% formalin for 15 min
at room temperature. Plates were washed and incu-
bated with 0.2 ml of Hanks’ balanced salt solution con-
taining 1% normal goat serum for 30 min. The blocking
buffer was then removed and 50 ml of a 1:1,000 dilution
of HTNV-specific mouse hyperimmune ascitic fluid
(HMAF) were added to the appropriate wells for 1.5 hr
at 35°C. After the plates were washed three times, 45
ml of a 1:2,000 dilution of peroxidase-labeled anti-
mouse IgG antibody were added to all wells and they
were incubated for 1.5 hr at 35°C. Plates were then
washed five times and 80 ml of ABTS substrate
(Kirkegaard and Perry) were added. After a 30 min
incubation at 35°C, OD were read spectrophotometri-
cally at 414 nm. All specimens were tested in duplicate.
All NT-ELISA titers are expressed as the reciprocal of
the highest serum dilution, which resulted in a 50%
reduction in absorbance of the negative controls.
IgG ELISA
IgG antibodies to HTNV were measured by coating
Immulon II plates (Dynatech) with 55 ml per well of
sucrose-purified HTNV diluted in phosphate-buffered
saline (PBS) (usually 1:50) overnight at 35°C. Plates
were blocked with PBS containing 1% normal goat se-
rum. Test sera, diluted 1:100 in blocking buffer, were
added to triplicate wells. The plates were incubated for
1.5 hr at 35°C, and were then washed three times.
Horseradish peroxidase-labeled anti-mouse IgG
(Kirkegaard and Perry, Gaithersburg, MD) (40 ml/well)
was added. After another incubation for 1.5 hr at 35°C,
the plates were washed four times and 80 ml of ABTS
substrate was added to each well. After 30 min, OD
were read spectrophotometrically at 414 nm. OD read-
ings of wells containing human prevaccination sera
that were negative for HTNV antibodies were sub-
tracted from test results. OD readings $ 0.2 were con-
sidered positive.
Lymphocyte Proliferation Assays
Assays were performed essentially as described pre-
viously [Schmaljohn et al., 1995]. Briefly, mononuclear
cells were plated at 2 × 105 per well in U-bottom plates
in the presence of varying dilutions of antigens or con-
trols. Culture medium consisted of serum-free medium
(X-VIVO-15) supplemented with 1% fresh autologous
plasma. For VACV and mock-VACV antigens, Vero cell
Fig. 1. (C) Geometric mean titers (GMT) of neutralizing antibodies for all individuals in each group at each assay point are shown. The assay
lower limit was 1:10 dilution of each serum. For calculation purposes, negative samples were assigned a value of 5.
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lysates were pelleted through 36% sucrose and infec-
tivity inactivated by irradiating. Antigen dilutions
were typically 10−3, 10−4, 10−5, and 10−6 (final concen-
trations in 0.2-ml cultures). Sucrose gradient-purified
HTNV and SNV antigens were tested at dilutions of
10−2, 10−3, and 10−4. Results shown are from a single
“optimal” antigen dilution. The stimulation index (SI)
was calculated as test cpm/medium control cpm.
Samples incorporating more than 3,000 cpm of 3H-
thymidine and with SI $ 3 were considered positive.
RESULTS AND DISCUSSION
Phase I: Dose Escalation
The Phase I study for the HFRS vaccine began as an
open label inoculation of four individuals with docu-
mented VACV vaccination (Group 1), followed by in-
oculation of three successive groups of VACV-naive vol-
unteers with dose escalation (Groups 2–4). All indi-
viduals received the vaccine subcutaneously (s.c.).
There was a 21-day interval between each group to
allow for observation of potential adverse reactions.
Safety was evaluated by the clinical response to
VACV and clinical laboratory findings. There were no
significant adverse reactions. Two volunteers receiving
the 3.4 × 106-PFU dose developed small, cutaneous pox
lesions (volunteers 10 and 12, Fig. 1), which healed
uneventfully. One recipient of the highest vaccine dose
had residual injection site tenderness for 6 days posti-
noculation. In situ ELISA assays [McClain et al., 1997]
were performed to determine if the volunteers became
viremic. No VACV was detected in blood samples col-
lected from the volunteers at any time point.
Neutralizing antibodies to HTNV G1 or G2 are
known to passively protect rodents from challenge
[Schmaljohn et al., 1990]; consequently, elicitation of
neutralizing antibody responses is a widely accepted
correlate of immunogenicity. To assess immunogenic-
ity of the recombinant vaccine in the dose-escalation
study, we measured neutralizing antibody responses to
HTNV by PRNT. We also measured neutralizing re-
sponses to VACV to gauge infectivity of the vaccine. As
expected, all Group 1 volunteers (i.e., who had been
immunized previously with VACV) had neutralizing
antibodies to VACV at day 0 (data not shown) and after
receiving the baseline dose of the recombinant vaccine
(3.4 × 105 PFU) (Fig. 1A). None of the volunteers in the
VACV-naive groups had neutralizing antibodies to
VACV at day 0, but after vaccination, all but two (vol-
unteer 6 in Group 2, and volunteer 11 in Group 3) de-
veloped neutralizing antibodies to VACV (Fig. 1A).
None of the volunteers had neutralizing antibodies to
HTNV at day 0. None of the VACV-immune volunteers
(Group 1) developed neutralizing antibodies to HTNV
after receiving the baseline dose of the recombinant
vaccine (Fig. 1B). Neutralizing antibodies to HTNV
were detected in one volunteer in each of Groups 2 and
3 and in three of four volunteers in Group 4 (Fig. 1B).
Therefore, in this study, the full-strength vaccine dose
was superior to lower doses both for VACV infectivity
and for eliciting neutralizing antibodies to HTNV.
To examine the anamnestic response to the vaccine,
available individuals were revaccinated with the high-
est dose of the vaccine approximately 1 year after their
initial vaccination. Participating in the study were vol-
unteers 1, 2, and 3 from Group 1, volunteer 6 volunteer
from Group 2, all four volunteers from Group 3, and
volunteers 14, 15, and 16 from Group 4. Although only
one volunteer in Group 3 had detectable neutralizing
antibodies to HTNV after the initial vaccination, all
four developed good responses after the booster inocu-
lation of the full-strength dose of vaccine (Fig. 1B).
These individuals also all developed higher responses
to VACV than were observed after the initial vaccina-
tion (Fig. 1A). Similarly, increased titers of neutraliz-
ing antibodies to VACV were observed in all three of
the revaccinated Group 4 volunteers (Fig. 1A). Two of
the three boosted individuals in Group 4 developed
rises in antibody titers to HTNV as compared with ti-
ters measured immediately before the boost (which
were # 10), but their titers were twofold to fourfold
lower than observed after the initial vaccination (Fig.
1B). The other boosted volunteer (volunteer 16) re-
mained negative for neutralizing antibodies to HTNV
despite a rise in titer to VACV (Fig. 1A, B).
The geometric mean titers (GMT) of neutralizing an-
tibodies to HTNV were calculated for all bleeds in each
group. The Group 4 GMT demonstrated that the high-
est neutralizing antibody response was achieved ap-
proximately 2 weeks after vaccination, and that a rapid
anamnestic response appeared upon boosting at 1 year
(Fig. 1C). For Group 3, boosting at 1 year resulted in a
delayed response, more similar to a primary than an
anamnestic response to HTNV (Fig. 1C).
Although cell-mediated immune responses (CMI) to
hantaviruses may not be the primary means of pre-
venting infection, it is likely that it plays a role in re-
solving established infections. In addition, because
CMI are more cross-reactive among hantaviruses than
neutralizing antibody responses [Asada et al., 1989],
measuring CMI might offer insights into cross-
protective properties of a vaccine. To assess elicitation
of CMI by the recombinant vaccine, we performed lym-
phocyte transformation (LT) assays. In addition to
HTNV and VACV antigen, we measured responses to
SNV, an etiologic agent of hantavirus pulmonary syn-
drome. At day 0, all four individuals in the VACV-
immune Group (Group 1) had LT responses to VACV,
but none had responses to HTNV or SNV (data not
shown). One individual in a VACV-naive group (volun-
teer 13, Group 4) had a low SI to VACV at day 0, but all
others were negative. Interestingly, at day 0, one per-
son in Group 3 (volunteer 12, Table I) had a prolifera-
tive response to SNV (SI 4 25.4) and a lesser response
to HTNV (SI 4 7.4). It is possible that this reflected a
pre-existing hantavirus exposure.
After vaccination, one person in Group 3 (volunteer
9) and one person in Group 4 (volunteer 16) failed to
develop an LT response to any of the three viruses, but
all of the others had positive LT responses to VACV
(Table I). Seven volunteers displayed proliferative re-
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sponses to HTNV and most of those had responses to
SNV (Table I).
The volunteer in Group 4 who initially had no LT
response to any of the viruses (volunteer 16) did de-
velop an LT response to all three viruses when boosted
1 year later (Table I). Therefore, although this volun-
teer did not have neutralizing antibodies to HTNV, a
cellular immune response was detected in the lympho-
cyte proliferation assay.
Phase I: Comparison of One vs. Two
Subcutaneous Inoculations
In our earlier studies, we found that two vaccinations
with the recombinant VACV vaccine were better than
one for eliciting neutralizing and protective immunity
to HTNV in hamsters [Schmaljohn et al., 1992]. To
compare the immunogenicity of this vaccine after one
or two s.c. inoculations of humans, a group of 12 VACV-
naive individuals (Group 5) was randomly divided into
two subgroups (5A and 5B). Both groups received a
full-strength dose of vaccine (3.4 × 107 PFU), and those
in subgroup 5B received a boost of the same dose 42
days later. None of the volunteers had neutralizing an-
tibodies to HTNV or VACV at day 0. After one injection
of the recombinant vaccine, 9 of the 12 volunteers de-
veloped neutralizing antibodies to VACV (Fig. 2A).
Four of the 12 volunteers (volunteers 5 and 6 in group
5A and volunteers 7 and 10 in Group 5B) developed
neutralizing antibodies to HTNV (Fig. 2B). After a sec-
ond inoculation, all 6 volunteers in Group 5B had neu-
tralizing antibodies to both HTNV and VACV (Fig. 2A,
B). As in the first portion of the dose-escalation study,
the GMT of neutralizing antibodies to HTNV or VACV
peaked at 14 days after the initial vaccination and then
declined to baseline levels by day 42 (data not shown).
The GMT of the group receiving a booster vaccination
peaked at day 7 after boosting and remained at that
level for at least four weeks, after which the titer
gradually declined (data not shown). Therefore, results
obtained for Groups 1–5 indicated that two inocula-
tions were better than one for eliciting neutralizing an-
tibody responses to HTNV or to VACV and that a sec-
ond inoculation evoked an anemnestic response.
Lymphocyte transformation assays were performed
on blood samples collected from individuals in Groups
5A and 5B at days 0, 42, 56, and 63 after vaccination.
At day 0, one person showed a weak LT response to
HTNV and SNV (volunteer 8, Group 5B, SI < 5), but the
rest were negative for the hantaviruses (data not
shown). This same individual had a weak LT response
to VACV (SI < 5) at day 0 as did volunteers 5 and 6 in
Group 5A and volunteer 10 in Group 5B. Volunteer 12
in Group 5B had a moderate LT response to VACV at
day 0 (SI 4 11). None of these individuals had neutral-
izing antibody responses at day 0, so we still considered
them to be VACV-naive.
After one vaccination all volunteers had LT re-
sponses to VACV and all but one in Group 5A (volun-
teer 2) had LT responses to HTNV and SNV (Table II).
The responses to HTNV could be detected in one of
these five volunteers at day 42, but not in the other four
volunteers until day 63 after vaccination. Similarly,
TABLE I. Lymphocyte Proliferative Responses of Volunteers in Groups 1–4 of
the Phase I Dose-Escalation Study of the Recombinant VACV Vaccine for
Hantaan Virus
Group
VACV immunity
Dose Volunteer
SI SI, 1-year boost
VACV HTNV SNV VACV HTNV SNV
Group 1 1 25.8 <3 <3 46.6 3 <3
VACV-immune 2 74.2 3.7 <3 186.4 7.6 7.7
3.4 × 105 PFU 3 49.9 <3 <3 100.9 <3 <3
4 37 <3 <3 NA NA NA
Group 2 5 12.4 <3 <3 NA NA NA
VACV-naive 6 66.4 16.6 12.3 34 7.7 5.1
3.4 × 105 PFU 7 4.8 <3 <3 NA NA NA
8 7 <3 <3 NA NA NA
Group 3 9 <3 <3 <3 <3 <3 <3
VACV-naive 10 78.6 23.7 <3 53.7 6.7 3.9
3.4 × 106 PFU 11 9.6 12 9.1 10.2 9.1 9.4
12 128.7 56.7 16.3 18.3 15.9 6.1
Group 4 13 182.8 16.5 8.5 NA NA NA
VACV-naive 14 24.1 16.6 6.3 33.5 16 6.4
3.4 × 107 PFU 15 17.3 <3 3.3 4.1 <3 3.2
16 <3 <3 <3 12.9 8.1 5.1
VACV, vaccinia virus; SI, stimulation index; HTNV, Hantaan virus; Sin Nombre virus; PFU,
plaque-forming units; NA, no sample available.
Blood samples were collected from volunteers periodically between days 0 and 84 after the
initial vaccination with the recombinant VACV vaccine. Proliferative responses were mea-
sured for all volunteers at day 0, and from at least 2 other samplings. Responses to HTNV,
SNV, and VACV were measured for each volunteer for at least three different samples. The
highest SI achieved at day 42, 56, or 70 after initial vaccination is displayed. For volunteers
who received a boost 1 year after their initial vaccination, SI of samples collected between 4
and 6 weeks after the boost are shown.
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two individuals in group 5B had LT responses at day 42
(before they received a booster vaccination) and all 6
had LT responses at day 63 (after they received a
booster inoculation) (Table II).
Phase I: Comparison of Subcutaneous
Inoculation and Scarification
Subcutaneous delivery of the vaccine was intended to
avoid the development of cutaneous pox lesions and
inadvertent spread of the virus. Nevertheless, four in-
dividuals in Groups 1–5 did develop cutaneous lesions.
This prompted us to design an additional Phase I pro-
tocol to compare s.c. inoculation to scarification. The
trial consisted of an open-label inoculation of six
VACV-naive individuals (Group 1) with the recombi-
nant vaccine by scarification (pricks with a bifurcated
needle dipped in vaccine) over the deltoid region of the
arm. Twelve additional volunteers with documented
histories or evidence of previous VACV vaccination
(VACV-immune) were randomized between Groups 2
and 3. Group 2 received the vaccine by scarification and
Group 3 by s.c. inoculation. All volunteers received a
second inoculation 6 weeks later. The first scarification
was administered with three pricks for VACV-naive
volunteers, and 15 pricks for VACV-immune volun-
teers. All volunteers received 15 pricks for the boost.
Five of the six volunteers (VACV-naive) in Group 1
developed cutaneous pox lesions typical of VACV vac-
cines after primary scarification and had neutralizing
antibody responses to VACV (Fig. 3A). Four of these
individuals developed neutralizing antibody responses
to HTNV after one vaccination and all six had neutral-
izing antibodies after a second scarification (Fig. 3B).
In contrast, none of the VACV-immune volunteers who
received the vaccine by scarification (Group 2) devel-
oped neutralizing antibodies to HTNV (Fig. 3B). Two of
the VACV-immune individuals who received the vac-
cine by s.c. injection (Group 3) developed neutralizing
antibodies to HTNV after one injection and three had
neutralizing antibodies after the second vaccination
(Fig. 3B). For these six individuals, there was not an
obvious correlation between developing an immune re-
sponse to HTNV and having low preexisting antibody
titers to VACV. That is, the three volunteers who de-
veloped neutralizing antibodies to HTNV after two s.c.
inoculations had titers to VACV of 5, 66, and 104 at day
Fig. 2. Comparison of neutralizing antibody titers of volunteers
receiving one subcutaneous (s.c.) inoculation (Group 5A) and two s.c.
inoculations (Group 5B) of the recombinant vaccine. Periodic blood
samples were collected from volunteers from day 0 to day 365 after
vaccination. The highest reciprocal neutralizing antibody titer mea-
sured at any of the assay points to vaccinia virus (VACV) (A) or
Hantaan virus (HTNV) (B) are displayed.
TABLE II. Lymphocyte Proliferative Responses of
Volunteers in the Phase I Comparison of One vs. Two
Subcutaneous Inoculations of the Recombinant VACV
Vaccine for Hantaan Virus
Group
VACV immunity
Dose
Number of
vaccinations Volunteer
SI
VACV HTNV SNV
Group 5A 1 69.3 7.5 8.4
VACV-naive 2 39.3 <3 <33 109.6 93.3 80.2
3.4 × 107 PFU 4 27 19.3 10.9
1 vaccination 5 31.8 9.5 56 18.6 15.5 10.7
Group 5B 7 52.4 6.2 5.1
VACV-naive 8 58.1 51.4 54.89 43 5.8 9
3.4 × 107 PFU 10 39.9 15.1 12.8
2 vaccinations 11 35.2 10.2 7.112 41.2 10.7 11.5
VACV, vaccinia virus; SI, stimulation index; HTNV, Hantaan virus;
SNV, Sin Nombre virus; PFU, plaque-forming units.
Lymphocyte proliferation responses were measured on samples col-
lected from volunteers on day 0, 42, 56, and 63 after vaccination with
the recombinant VACV vaccine. Individuals in group 5B received a
second vaccination at day 42. The highest SI achieved at any of the
days to VACV, HTNV, or SNV after vaccination are listed.
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0 of the study (volunteers 15, 17, 18, respectively, Fig.
3A, B). The volunteers who did not respond to HTNV
after two vaccinations had day 0 titers to VACV of
30, 20, and 23 (volunteers 13, 14, 16, respectively, Fig.
3A, B).
Comparing GMT of neutralizing antibodies for the
three groups in this study indicated that scarification
of VACV-naive volunteers resulted in the highest neu-
tralizing antibody levels to HTNV with the lowest neu-
tralizing responses to VACV (not shown). As with s.c.
inoculation of VACV-naive volunteers, scarification of
naive volunteers resulted in peak GMT of neutralizing
antibodies to HTNV or VACV 2–3 weeks after vaccina-
tion; however, a scarification boost at day 42 did not
result in a noticeable anamnestic response to either
HTNV or VACV (not shown).
All but one of the VACV-naive volunteers who were
scarified displayed LT responses to VACV and HTNV
(volunteer 5) (Table III). However, only two of the scari-
fied VACV-immune volunteers had an LT response to
HTNV (Table III). Five of the six VACV-immune vol-
unteers who received the s.c. inoculation developed LT
responses to HTNV, although responses were generally
lower than those observed in the scarified, VACV-naive
individuals. These data suggest that scarification
would be a useful means of inoculating individuals who
were not previously immunized with VACV, but s.c.
vaccination is better for VACV-immune individuals.
Phase II Clinical Trial
The Phase II study was double-blinded and placebo-
controlled. Of the 142 volunteers enrolled, 74 were
VACV-immune and 68 were VACV-naive (as deter-
mined by volunteer’s history, absence of vaccination
scar, and absence of preexisting antibody to VACV in
ELISA and neutralization assays). A total of 115 vol-
unteers received the vaccine (3.4 × 107 PFU) and 27
received a saline placebo. Although all were scheduled
to receive two s.c. vaccinations 6 weeks apart, 22 of the
vaccinees and four of the controls did not return for a
second inoculation. Three volunteers were excluded be-
cause of improper vaccine administration; therefore, a
Fig. 3. Comparison of neutralizing antibody responses to Hantaan
virus (HTNV) (A) and vaccinia virus (VACV) (B) after vaccination
once or twice by scarification or by subcutaneous (s.c.) inoculation.
The dose delivered by scarification was approximated based on the
amount of liquid that typically adhered to the bifurcated needle. Pe-
riodic blood samples were collected from day 0 to day 365 after vac-
cination and assayed for neutralizing antibodies by plaque reduction
neutralization tests (PRNT). The highest reciprocal titer measured for
each individual at any of the sampling times are shown.
TABLE III. Lymphocyte Proliferative Responses of
Volunteers in the Phase I Comparison of Scarification and
Subcutaneous Inoculation of the Recombinant Vaccine for
Hantaan Virus
Group
VACV immunity
Route of inoculation Volunteer
SI
VACV HTNV SNV
Group 1 1 118 38.7 5.5
VACV-naive 2 8.1 3.9 <3
Scarification 3 18.8 14.5 5.1
4 47.2 29.7 23.2
5 <3 <3 <3
6 8.3 10.3 <3
Group 2 7 41.6 5.8 6.0
VACV-immune 8 52.6 <3 <3
Scarification 9 22.9 <3 3.6
10 25.5 <3 4.9
11 21.7 <3 <3
12 17.4 3.5 3.0
Group 3 13 13.5 4.9 5.6
VACV-immune 14 42.5 6.3 <3
Subcutaneous 15 45.2 <3 10.1
16 26.2 7.0 6.5
17 92.2 8.6 4.1
18 14.8 6.4 3.3
VACV, vaccinia virus; SI, stimulation index; HTNV, Hantaan virus;
SNV, Sin Nombre virus.
Lymphocyte proliferative responses were determined for samples col-
lected on days 0 and on at least two of three samples collected at days
55, 93 and 118 after vaccination. The highest SI achieved at any of the
time points is shown.
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final group of 112 volunteers who received the recom-
binant vaccine were assessed (Table IV). Approxi-
mately three fourths of the VACV-naive volunteers
who received both vaccinations developed neutralizing
antibody titers to HTNV; however, only about one
fourth of the VACV-immune individuals were PRNT-
positive for HTNV after two vaccinations (Table IV).
One of 12 volunteers (8%) with neutralizing antibody
titers of > 40 to VACV at day 0 developed a neutralizing
antibody response to HTNV after two vaccinations (ti-
ter 4 10). Six of 16 (38%) of volunteers with titers to
VACV at day 0 of $ 20 # 40 developed neutralizing
responses to HTNV after two vaccinations (range 10–
80). Four of 19 volunteers (21%) with day 0 neutraliz-
ing antibody titers to VACV of < 20 developed neutral-
izing responses to HTNV after two vaccinations (range
10–640). Thus there appeared to be a trend toward
better responses to HTNV in volunteers with lower pre-
existing antibody titers to VACV.
Comparing the GMT of neutralizing antibodies at
each time point tested revealed that the peak primary
response to HTNV occurred in VACV-naive individuals
at 2–3 weeks after vaccination, but declined to baseline
levels by 7 weeks if a booster inoculation was not ad-
ministered (Fig. 4). Likewise, VACV neutralizing anti-
body levels were higher after the booster inoculation
than after a single inoculation of the recombinant vac-
cine (data not shown).
As in the Phase I studies, a minority of vaccinees
developed cutaneous pox lesions. In the VACV-immune
group, none of three volunteers who developed pox le-
sions had neutralizing antibodies to HTNV. In the
VACV-naive group, 9 of 11 (78%) of the volunteers who
developed lesions had neutralizing antibodies to
HTNV. The GMT of neutralizing antibodies to HTNV
for these 9 vaccinees was 80. For individuals who did
not develop pox lesions, 68% of VACV-naive individu-
als had neutralizing antibodies to HTNV, with GMT of
160. Hence, there was no clear indication in the Phase
II study that development of a cutaneous pox lesion
correlated with a higher neutralizing antibody re-
sponse to HTNV.
To determine if PRNT reflected seroconversion of all
of the volunteers, IgG ELISA was performed with pu-
rified, inactivated HTNV as antigen and a 1:100 dilu-
tion of each serum. Unlike PRNT, ELISA was expected
to detect antibodies to nucleocapsid protein and non-
neutralizing antibodies to G1 or G2. In addition to
those individuals who displayed neutralizing antibod-
ies, the ELISA detected five VACV-naive and four
VACV-immune volunteers with antibodies to HTNV
(all of whom had received two vaccinations). Thus an-
Fig. 4. Geometric mean (GMT) neutralizing anti-
body responses to Hantaan virus (HTNV) of volun-
teers enrolled in the Phase II clinical study. Of the
112 volunteers in the final reporting groups, ap-
proximately half were already immune to vaccinia
virus (VACV-immune) and half were not immune to
VACV (VACV-naive). Although all were scheduled
to receive two subcutaneous (s.c.) vaccinations 6
weeks apart, 22 subjects did not return for a second
inoculation. GMT of neutralizing antibodies to Han-
taan virus (HTNV) are shown separately for VACV-
immune or VACV-naive volunteers receiving one or
two vaccinations.
TABLE IV. Neutralizing Antibody Responses of Volunteers in the Phase II Clinical Study of the Recombinant VACV
Vaccine for Hantaan Virus
VACV-immunity Boost
Number of
volunteers
HTNV PRNT50% VACV PRNT50%
%
Positive Range GMT
%
Positive Range GMT
Naive yes 43 72 10–640 160 98 10–640 49
Naive no 9 44 20–80 40 67 10–68 21
Immune yes 47 26 10–80 24 100 20–640 270
Immune no 13 8 10 10 100 16–640 151
VACV, vaccinia virus; HTNV, Hantaan virus; GMT, geometric mean titers; PRNT, plaque reduction neutralization test.
GMTs were calculated by using the highest antibody dilution of each volunteer that reduced the number of HTNV or VACV plaques by 50%
(PRNT50%) as compared with virus controls not incubated with sera.
84 McClain et al.
tibody responses measured by PRNT or ELISA to
HTNV were detected in 84% of VACV-naive and in 32%
of the VACV-immune volunteers who received two
vaccinations.
CONCLUSION
These data indicate that the recombinant vaccine is
safe and well tolerated in healthy volunteers. Two vac-
cinations of VACV-naive individuals resulted in good
seroconversion rates and elicitation of neutralizing an-
tibodies to HTNV. However, in the Phase II study, neu-
tralizing antibodies were not consistently high, and de-
clined to near baseline levels over 3–6 months. Because
VACV is no longer routinely administered for preven-
tion of smallpox, it is likely that this vaccine would be
efficacious in a target population of VACV-naive young
adults.
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